Several studies involving transcription factors have indicated therapeutic effects in NASH (67, 68), for example, transcription factors including PPARs, LXR and FXR are mainly known for their roles in altering lipid metabolism in NAFLD/NASH development. Here, NR1H4 is linked to metabolic dysfunction-associated steatotic liver disease.